INTRODUCTION: In silico tools capable of predicting the functional consequences of genomic differences between individuals, many of which are AI-driven, have been the most effective over the past two decades for non-synonymous single nucleotide variants (nsSNVs). When appropriately selected for the purpose of the study, a high predictive performance can be expected. In this feasibility study, we investigate the distribution of nsSNVs with an allele frequency below 5%. To classify the putative functional consequence, a tier-based filtration led by AI-driven predictors and scoring system was implemented to the overall decision-making process, resulting in a list of prioritised genes. METHODS: The study has been conducted on breast cancer patients of homogeneous ethnicity. Germline rare variants have been sequenced in genes that influence pharmacokinetic parameters of anticancer drugs or molecular signalling pathways in cancer. After AI-driven functional pathogenicity classification and data mining in pharmacogenomic (PGx) databases, variants were collapsed to the gene level and ranked according to their putative deleterious role. RESULTS: In breast cancer patients, seven of the twelve genes prioritised based on the predictions were found to be associated with response to oncotherapy, histological grade, and tumour subtype. Most importantly, we showed that the group of patients with at least one rare nsSNVs in cystic fibrosis transmembrane conductance regulator (CFTR) had significantly reduced disease-free (log rank, p = 0.002) and overall survival (log rank, p = 0.006). CONCLUSION: AI-driven in silico analysis with PGx data mining provided an effective approach navigating for functional consequences across germline genetic background, which can be easily integrated into the overall decision-making process for future studies. The study revealed a statistically significant association with numerous clinicopathological parameters, including treatment response. Our study indicates that CFTR may be involved in the processes influencing the effectiveness of oncotherapy or in the malignant progression of the disease itself.

3rd Faculty of Medicine Charles University Prague Czechia

Department of Oncosurgery MEDICON Prague Czechia

Department of Surgery EUC Hospital and University of Tomas Bata in Zlin Zlin Czechia

Institute for the Care for Mother and Child Prague Czechia

Laboratory of Pharmacogenomics Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czechia

Toxicogenomics Unit National Institute of Public Health Prague Czechia

Zobrazit více v PubMed

Malhotra GK, Zhao X, Band H, Band V. Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther. 201010(10):955–60. PubMed PMC

Schärfe CPI, Tremmel R, Schwab M, Kohlbacher O, Marks DS. Genetic variation in human drug-related genes. Genome Med. 2017;9(1):117. Available from: 10.1186/s13073-017-0502-5 PubMed DOI PMC

Kozyra M, Ingelman-Sundberg M, Lauschke VM. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet Med. 2017;19(1):20–9. PubMed

Nelson MR, Wegmann D, Ehm MG, Kessner D, St. Jean P, Verzilli C, et al. . An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science. 2012;337(6090):100–4. PubMed PMC

Gerek NZ, Liu L, Gerold K, Biparva P, Thomas ED, Kumar S. Evolutionary Diagnosis of non-synonymous variants involved in differential drug response. BMC Med Genomics. 2015;8(Suppl 1):S6. PubMed PMC

Tremmel R, Pirmann S, Zhou Y, Lauschke VM. Translating pharmacogenomic sequencing data into drug response predictions: how to interpret variants of unknown significance. Br J Clin Pharmacol [Internet]. [cited 2023 Oct 22];n/a(n/a). Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/bcp.15915 PubMed DOI

Gunning AC, Fryer V, Fasham J, Crosby AH, Ellard S, Baple EL, et al. . Assessing performance of pathogenicity predictors using clinically relevant variant datasets. J Med Genet. 2021;58(8):547–55. PubMed PMC

Tian Y, Pesaran T, Chamberlin A, Fenwick RB, Li S, Gau CL, et al. . REVEL and BayesDel outperform other in silico meta-predictors for clinical variant classification. Sci Rep. 2019;9(1):12752. PubMed PMC

Zhou Y, Mkrtchian S, Kumondai M, Hiratsuka M, Lauschke VM. An optimized prediction framework to assess the functional impact of pharmacogenetic variants. Pharmacogenomics J. 2019;19(2):115–126. PubMed PMC

Yazar M, Ozbek P. Assessment of 13 in silico pathogenicity methods on cancer-related variants. Comput Biol Med [Internet]. 2022;145:105434. PubMed

Cubuk C, Garrett A, Choi S, King L, Loveday C, Torr B, et al. . Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes. Genet Med. 2021;23(11):2096–104. PubMed PMC

Hlavac V, Kovacova M, Elsnerova K, Brynychova V, Kozevnikovova R, Raus K, et al. . Use of germline genetic variability for prediction of chemoresistance and prognosis of breast cancer patients. Cancers. 2018;10(12):511. PubMed PMC

Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. . RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–7. PubMed PMC

Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. . Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285–91. PubMed PMC

ALFA: allele frequency aggregator [Internet]. [cited 2023 Apr 23]. Available from: https://www.ncbi.nlm.nih.gov/snp/docs/gsr/alfa/

Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, et al. . REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. Am J Hum Genet. 2016;99(4):877–85. PubMed PMC

Dong C, Wei P, Jian X, Gibbs R, Boerwinkle E, Wang K, et al. . Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. Hum Mol Genet. 2015;24(8):2125–37. PubMed PMC

Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310–5. Available from: http://search.ebscohost.com/login.aspx?authtype=shib&custid=s1240919&profile=eds PubMed PMC

Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res. 2011;39(17):e118. Available from: 10.1093/nar/gkr407 PubMed DOI PMC

Ghosh R, Oak N, Plon SE. Evaluation of in silico algorithms for use with ACMG/AMP clinical variant interpretation guidelines. Genome Biol. 2017;18(1):225. PubMed PMC

Carter H, Douville C, Stenson PD, Cooper DN, Karchin R. Identifying mendelian disease genes with the variant effect scoring tool. BMC Genomics. 2013;14(Suppl 3):S3: PubMed PMC

Goecks J, Nekrutenko A, Taylor J; Galaxy Team . Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol. 2010;11(8):R86. PubMed PMC

PharmVar [Internet]. [cited 2023 Apr 22]. Available from: https://www.pharmvar.org/

Representation of clinical significance in ClinVar and other variation resources at NCBI [Internet]. [cited 2023 Apr 22]. Available from: https://www.ncbi.nlm.nih.gov/clinvar/docs/clinsig/

Lee S, Abecasis GR, Boehnke M, Lin X. Rare-variant association analysis: study designs and statistical tests. Am J Hum Genet. 2014;95(1):5–23. PubMed PMC

Lee NY, Hum M, Zihara S, Wang L, Myint MK, Lim DWT, et al. . Landscape of germline pathogenic variants in patients with dual primary breast and lung cancer. Hum Genomics. 2023;17(1):66. PubMed PMC

Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. . Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736–50. PubMed PMC

Knikman JE, Gelderblom H, Beijnen JH, Cats A, Guchelaar H, Henricks LM. Individualized dosing of fluoropyrimidine-based chemotherapy to prevent severe fluoropyrimidine-related toxicity: what are the options? Clin Pharmacol Ther. 2021;109(3):591–604. PubMed PMC

Carr DF, Turner RM, Pirmohamed M. Pharmacogenomics of anticancer drugs: personalising the choice and dose to manage drug response. Br J Clin Pharmacol. 2021;87(2):237–55. PubMed

Wojnowski L, Kulle B, Schirmer M, Schlüter G, Schmidt A, Rosenberger A, et al. . NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005;112(24):3754–62. PubMed

Zhang J, Wang Y, Jiang X, Chan HC. Cystic fibrosis transmembrane conductance regulator: emerging regulator of cancer. Cell Mol Life Sci. 2018;75(10):1737–56. PubMed PMC

FitzMaurice TS, Nazareth DS. Incidence of breast cancer in people with cystic fibrosis: a cause for concern? J Cyst Fibros [Internet]. 2021. [cited 2022 Aug 6];0(0). Available from: https://www.cysticfibrosisjournal.com/article/S1569-1993(21)02158-5/fulltext#relatedArticles PubMed

Dvorak P, Pesta M, Soucek P. ABC gene expression profiles have clinical importance and possibly form a new hallmark of cancer. Tumour Biol. 2017;39(5):1010428317699800. PubMed

Fukuda Y, Schuetz JD. ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol. 2012;83(8):1073–83. PubMed PMC

Lopes I, Altab G, Raina P, de Magalhães JP. Gene size matters: an analysis of gene length in the human genome. Front Genet. 2021;12:559998. PubMed PMC

Sahakyan AB, Balasubramanian S. Long genes and genes with multiple splice variants are enriched in pathways linked to cancer and other multigenic diseases. BMC Genomics. 2016;17(1):225. PubMed PMC

Fletcher JI, Williams RT, Henderson MJ, Norris MD, Haber M. ABC transporters as mediators of drug resistance and contributors to cancer cell biology. Drug Resist Updat. 2016;26:1–9. PubMed

Chen Z, Shi T, Zhang L, Zhu P, Deng M, Huang C, et al. . Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett. 2016;370(1):153–64. PubMed

Kanzaki A, Toi M, Neamati N, Miyashita H, Oubu M, Nakayama K, et al. . Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma. Jpn J Cancer Res. 2002;93(1):70–7. PubMed PMC

Nakayama K, Kanzaki A, Ogawa K, Miyazaki K, Neamati N, Takebayashi Y. Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP. Int J Cancer. 2002;101(5):488–95. PubMed